Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Nicolas Girard et al.|New England Journal of Medicine|2024Cited by 369
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Alexander I. Spira, Enriqueta Felip et al.|Future Oncology|2021Cited by 93